Küleon Bioscience
David Gilles worked as the Co-Founder and CTO at Küleon Bioscience, where they focused on developing novel compounds for the treatment of neuropsychiatric disorders. Before that, they were a Consultant at Phase 3 Labs Solutions, specializing in ISO 17025 accreditation, chemical and microbial analytics, and laboratory build-outs for cannabis testing. David also served as the R&D Lab Manager at Biosynthetic Technologies, where they prepared estolides for examination as potential base oils for various applications. Prior to that, they were the VP of Scientific Operations at Spectra Analytical Laboratories dba SteepHill Hawaii, where they oversaw the creation and modification of SOPs and regulatory operations for sample testing.
David Gilles completed their Bachelor of Science in Chemistry at the University of Hawaii at Manoa from 2007 to 2012. David then pursued a Master of Science in Organic Chemistry at the same university from 2012 to 2016.
This person is not in any teams
This person is not in any offices
Küleon Bioscience
Küleon is a drug discovery company focused on developing novel serotonergic drugs for the targeted treatment of various neuropsychiatric diseases and disorders. We’ve created a proprietary portfolio of serotonin receptor ligands designed to target neurocircuit abnormalities in the brain that are responsible for difficult-to-treat disorders such as schizophrenia and depression. We have successfully identified several preclinical leads that have significantly improved agonism characteristics such as low-to-no hallucinogenic or cardiotoxic liability, as well as modified PK/PD profiles when compared to other known atypical antipsychotics and serotonergic drugs. Serotonergic drugs have the potential to address multiple indications affecting large population groups that make up extremely sizable markets. This is because many of the current SSRIs and non-selective serotonin receptor agonists were not designed with an eye towards functional selectivity. Our novel compounds are designed for functional selectivity via biased signalling mechanisms, potentially enhancing their therapeutic effect and reducing unwanted side effects. Our proprietary molecular scaffolds and compounds are novel and patentable, providing us with a tremendous strategic foothold in the market as companies continue to explore novel mechanisms of action for targeting neuropsychiatric diseases and disorders. We are collaborating with some of the world’s leading academic researchers and key opinion leaders in the serotonergic and atypical antipsychotic drug development space. Please reach out if you would like learn more about the work we are doing with our collaborators!